Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rybrevant
Pharma
FDA expands label for AZ's Tagrisso in NSCLC indication
The FDA has signed off on Tagrisso to become the first targeted therapy for unresectable, stage 3 EGFRm non-small cell lung cancer.
Kevin Dunleavy
Sep 26, 2024 10:52am
J&J earns 3rd NSCLC nod in 7 months for surging Rybrevant
Sep 20, 2024 11:00am
J&J builds case for Tagrisso rival with survival analysis
Sep 8, 2024 2:07pm
J&J's Tagrisso challenger wins FDA nod in first-line lung cancer
Aug 20, 2024 10:26am
Despite J&J's full nod, FDA endorses Dizal's accelerated plan
Jun 26, 2024 11:08am
ASCO surprise: J&J's injectable Rybrevant works better than IV
May 31, 2024 5:45pm
